ReviewBiomolecules2023
Systemic Photoprotection in Melanoma and Non-Melanoma Skin Cancer.
Review in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Effects of Eight-Week Supplementation Containing Red Orange andNutrients · 2025Trial
- Integrative analysis of adiponectin-related genes reveals immune subtypes and prognostic significance in melanoma.Future science OA · 2026Article
- Clinical Patterns in Patients with Basal Cell Carcinoma: A 10-Year Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Antitumor properties of fungal-derived compounds: potential applications in skin cancer therapy.Molecular biology reports · 2026Review
- Skin Cancer Prevention and Antiaging: Role of Nicotinamide.International journal of molecular sciences · 2026Review
- Transferosomes as Advanced Nanocarriers for Enhanced Drug Delivery in Skin Cancer Therapy: A Comprehensive Review.Applied biochemistry and biotechnology · 2026Review
- Global regional and national burden of nonmelanoma skin cancer from 1990 to 2021 based on the global burden of disease 2021 study.Discover oncology · 2026Article
- Global Burden and Drivers of Cutaneous Malignant Melanoma Among Women Aged 55 and Older.International journal of women's health · 2026Article
- Non-surgical Synergistic Interventions for the Treatment of Skin Cancer.Current pharmaceutical design · 2026Review
- Optimization, Preparation, and Cytotoxic Potential ofCurrent topics in medicinal chemistry · 2026Article
- Bioinformatics and immunoinformatics approaches in the design of a multi-epitope vaccine targeting CTLA-4 for melanoma treatment.Molecular diversity · 2025Article
- Cytotoxic Activity of Essential Oils from Middle Eastern Medicinal Plants on Malignant Keratinocytes.Molecules (Basel, Switzerland) · 2025Article
- Advanced Therapies for Inflammatory Bowel Disease and Risk of Skin Cancer: What's New?Cancers · 2025Review
- Micronutrients and skin cancer risk: a Mendelian randomization study.World journal of surgical oncology · 2025Article
- Molecular and immune landscape of melanoma: a risk stratification model for precision oncology.Discover oncology · 2025Article
- The diagnostic potential of Asprosin and Meteorin-like proteins in basal and squamous cell carcinomas.Archives of dermatological research · 2025Article
- Electrochemical and Optical Carbon Dots and Glassy Carbon Biosensors: A Review on Their Development and Applications in Early Cancer Detection.Micromachines · 2025Review
- The multiple biological activities of hyperoside: from molecular mechanisms to therapeutic perspectives in neoplastic and non-neoplastic diseases.Frontiers in pharmacology · 2025Review
- Personalized Photoprotection: Expert Consensus and Recommendations From a Delphi Study Among Dermatologists.Photodermatology, photoimmunology & photomedicine · 2025Article
- Trends and emerging frontiers of photodynamic therapy for non-melanoma skin cancer (1979-October 2024): a bibliometric analysis.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-melanoma skin cancers (NMSCs), which include basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and actinic keratosis (AK), are the most common cancer diseases in the Caucasian race. If diagnosed late and improperly treated, BCC and SCC can become locally advanced and metastasize. Malignant melanoma (MM) is less frequent but more lethal than NMSC. Given the individual and social burdens of skin cancers, performing an adequate prevention is needed. Ultraviolet (UV) ray exposure is one of the main risk factors for skin cancer. Thus, the first-choice prevention strategy is represented by photoprotection that can be both topical and systemic. The latter consists of the oral administration of molecules which protect human skin against the damaging effects of UV rays, acting through antioxidant, anti-inflammatory, or immunomodulator mechanisms. Although several compounds are commonly used for photoprotection, only a few molecules have demonstrated their effectiveness in clinical trials and have been included in international guidelines for NMSC prevention (i.e., nicotinamide and retinoids). Moreover, none of them have been demonstrated as able to prevent MM. Clinical and preclinical data regarding the most common compounds used for systemic photoprotection are reported in this review, with a focus on the main mechanisms involved in their photoprotective properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.